{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:55:41Z","timestamp":1787003741852,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-81396-w","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T10:20:17Z","timestamp":1732702817000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Detection of enoxaparin and argatroban by use of the novel viscoelastic coagulometer ClotPro"],"prefix":"10.1038","volume":"14","author":[{"given":"Johannes","family":"Gratz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Ulbing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Dibiasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Wiegele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Quehenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Schaden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"issue":"2","key":"81396_CR1","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.chest.2021.08.050","volume":"161","author":"SM Fernando","year":"2022","unstructured":"Fernando, S. M. et al. VTE Prophylaxis in critically ill adults: a systematic review and network Meta-analysis. Chest 161 (2), 418\u2013428 (2022).","journal-title":"Chest"},{"issue":"2","key":"81396_CR2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/EJA.0000000000000707","volume":"35","author":"J Duranteau","year":"2018","unstructured":"Duranteau, J., Taccone, F. S., Verhamme, P., Ageno, W. & ESA VTE Guidelines Task Force. European guidelines on perioperative venous thromboembolism prophylaxis: intensive care. Eur. J. Anaesthesiol. 35 (2), 142\u2013146 (2018).","journal-title":"Eur. J. Anaesthesiol."},{"issue":"5","key":"81396_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/MBC.0000000000001133","volume":"33","author":"M Bachler","year":"2022","unstructured":"Bachler, M. et al. Thromboprophylaxis with argatroban in critically ill patients with sepsis: a review. Blood Coagul Fibrinolysis. 33 (5), 239\u2013256 (2022).","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"22","key":"81396_CR4","doi-asserted-by":"publisher","first-page":"5369","DOI":"10.3390\/jcm10225369","volume":"10","author":"FS Neuenfeldt","year":"2021","unstructured":"Neuenfeldt, F. S., Weigand, M. A. & Fischer, D. Coagulopathies in Intensive Care Medicine: Balancing Act between thrombosis and bleeding. J. Clin. Med. 10 (22), 5369 (2021).","journal-title":"J. Clin. Med."},{"issue":"4","key":"81396_CR5","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/cc4975","volume":"10","author":"M Levi","year":"2006","unstructured":"Levi, M. & Opal, S. M. Coagulation abnormalities in critically ill patients. Crit. Care. 10 (4), 222 (2006).","journal-title":"Crit. Care"},{"issue":"2","key":"81396_CR6","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/ajh.22222","volume":"87","author":"E Gehrie","year":"2012","unstructured":"Gehrie, E. & Laposata, M. Test of the month: the chromogenic antifactor xa assay. Am. J. Hematol. 87 (2), 194\u2013196 (2012).","journal-title":"Am. J. Hematol."},{"issue":"4","key":"81396_CR7","doi-asserted-by":"publisher","first-page":"5844","DOI":"10.4081\/hr.2015.5844","volume":"7","author":"MY Wei","year":"2015","unstructured":"Wei, M. Y. & Ward, S. M. The Anti-factor Xa Range for low Molecular Weight Heparin Thromboprophylaxis. Hematol. Rep. 7 (4), 5844 (2015).","journal-title":"Hematol. Rep."},{"issue":"8","key":"81396_CR8","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1007\/s00134-022-06744-8","volume":"48","author":"J Gratz","year":"2022","unstructured":"Gratz, J., Wiegele, M., Dibiasi, C. & Schaden, E. The challenge of pharmacological thromboprophylaxis in ICU patients: anti-FXa activity does not constitute a simple solution. Intensive Care Med. 48 (8), 1116\u20131117 (2022).","journal-title":"Intensive Care Med."},{"issue":"2","key":"81396_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.accpm.2020.03.012","volume":"39","author":"Y Gruel","year":"2020","unstructured":"Gruel, Y. et al. Diagnosis and management of heparin-induced thrombocytopenia. Anaesth. Crit. Care Pain Med. 39 (2), 291\u2013310 (2020).","journal-title":"Anaesth. Crit. Care Pain Med."},{"issue":"6","key":"81396_CR10","first-page":"305","volume":"72","author":"S van Roessel","year":"2014","unstructured":"van Roessel, S., Middeldorp, S., Cheung, Y. W., Zwinderman, A. H. & de Pont, A. C. J. M. Accuracy of aPTT monitoring in critically ill patients treated with unfractionated heparin. Neth. J. Med. 72 (6), 305\u2013310 (2014).","journal-title":"Neth. J. Med."},{"issue":"2","key":"81396_CR11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/ijlh.13757","volume":"44","author":"S Guy","year":"2022","unstructured":"Guy, S. et al. Laboratory methods for monitoring argatroban in heparin-induced thrombocytopenia. Int. J. Lab. Hematol. 44 (2), 399\u2013406 (2022).","journal-title":"Int. J. Lab. Hematol."},{"issue":"6","key":"81396_CR12","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/bjh.18120","volume":"197","author":"M Marchetti","year":"2022","unstructured":"Marchetti, M. et al. Managing argatroban in heparin-induced thrombocytopenia: a retrospective analysis of 729 treatment days in 32 patients with confirmed heparin-induced thrombocytopenia. Brit J. Haem. 197 (6), 766\u2013790 (2022).","journal-title":"Brit J. Haem"},{"issue":"7","key":"81396_CR13","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/anae.14670","volume":"74","author":"J Gratz","year":"2019","unstructured":"Gratz, J. et al. Protocolised thromboelastometric-guided haemostatic management in patients with traumatic brain injury: a pilot study. Anaesthesia 74 (7), 883\u2013890 (2019).","journal-title":"Anaesthesia"},{"issue":"4","key":"81396_CR14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1055\/a-1232-7721","volume":"41","author":"J Gratz","year":"2021","unstructured":"Gratz, J., Oberladst\u00e4tter, D. & Sch\u00f6chl, H. Trauma-Induced Coagulopathy and massive bleeding: current hemostatic concepts and treatment strategies. Hamostaseologie 41 (4), 307\u2013315 (2021).","journal-title":"Hamostaseologie"},{"issue":"3","key":"81396_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/anae.15254","volume":"76","author":"D Oberladst\u00e4tter","year":"2021","unstructured":"Oberladst\u00e4tter, D. et al. A prospective observational study of the rapid detection of clinically-relevant plasma direct oral anticoagulant levels following acute traumatic injury. Anaesthesia 76 (3), 373\u2013380 (2021).","journal-title":"Anaesthesia"},{"issue":"5","key":"81396_CR16","first-page":"1031","volume":"135","author":"L Infanger","year":"2022","unstructured":"Infanger, L. et al. Characterization of 2 different Prothrombin Complex concentrates by different hemostatic assays in an in vitro hemodilution model. Anesth. Analg. 135 (5), 1031\u20131040 (2022).","journal-title":"Anesth. Analg"},{"issue":"10","key":"81396_CR17","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1097\/EJA.0000000000001202","volume":"37","author":"J Gratz","year":"2020","unstructured":"Gratz, J. et al. Comparison of fresh frozen plasma vs. coagulation factor concentrates for reconstitution of blood: an in vitro study. Eur. J. Anaesthesiol. 37 (10), 879\u2013888 (2020).","journal-title":"Eur. J. Anaesthesiol."},{"issue":"4","key":"81396_CR18","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/pst.185","volume":"4","author":"SA Julious","year":"2005","unstructured":"Julious, S. A. Sample size of 12 per group rule of thumb for a pilot study. Pharmaceut Statist. 4 (4), 287\u2013291 (2005).","journal-title":"Pharmaceut Statist"},{"issue":"1","key":"81396_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13054-023-04327-7","volume":"27","author":"R Rossaint","year":"2023","unstructured":"Rossaint, R. et al. The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition. Crit. Care. 27 (1), 80 (2023).","journal-title":"Crit. Care"},{"issue":"4","key":"81396_CR20","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/EJA.0000000000001803","volume":"40","author":"S Kietaibl","year":"2023","unstructured":"Kietaibl, S. et al. Management of severe peri-operative bleeding: guidelines from the European Society of Anaesthesiology and Intensive Care: second update 2022. Eur. J. Anaesthesiol. 40 (4), 226\u2013304 (2023).","journal-title":"Eur. J. Anaesthesiol."},{"issue":"1","key":"81396_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12959-021-00267-w","volume":"19","author":"P Groene","year":"2021","unstructured":"Groene, P. et al. Viscoelastometry for detecting oral anticoagulants. Thromb. J. 19 (1), 18 (2021).","journal-title":"Thromb. J."},{"issue":"7","key":"81396_CR22","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1055\/s-0042-1756304","volume":"48","author":"J B\u00f6sch","year":"2022","unstructured":"B\u00f6sch, J. et al. Low-molecular-weight heparin resistance and its viscoelastic Assessment in critically ill COVID-19 patients. Semin Thromb. Hemost. 48 (7), 850\u2013857 (2022).","journal-title":"Semin Thromb. Hemost."},{"key":"81396_CR23","doi-asserted-by":"publisher","first-page":"888451","DOI":"10.3389\/fmed.2022.888451","volume":"9","author":"C Dibiasi","year":"2022","unstructured":"Dibiasi, C., Gratz, J., Wiegele, M., Baierl, A. & Schaden, E. Anti-factor xa activity is not Associated with venous thromboembolism in critically ill patients receiving enoxaparin for Thromboprophylaxis: a retrospective observational study. Front. Med. (Lausanne). 9, 888451 (2022).","journal-title":"Front. Med. (Lausanne)"},{"key":"81396_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.thromres.2015.12.016","volume":"139","author":"A Vahtera","year":"2016","unstructured":"Vahtera, A., Vaara, S., Pettil\u00e4, V. & Kuitunen, A. Plasma anti-FXa level as a surrogate marker of the adequacy of thromboprophylaxis in critically ill patients: a systematic review. Thromb. Res. 139, 10\u201316 (2016).","journal-title":"Thromb. Res."},{"issue":"1","key":"81396_CR25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1160\/TH06-10-0607","volume":"98","author":"JE Love","year":"2007","unstructured":"Love, J. E., Ferrell, C. & Chandler, W. L. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb. Haemost. 98 (1), 234\u2013242 (2007).","journal-title":"Thromb. Haemost"},{"issue":"7\u20138","key":"81396_CR26","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1345\/aph.1R745","volume":"47","author":"DM Kennedy","year":"2013","unstructured":"Kennedy, D. M. & Alaniz, C. Apparent argatroban resistance in a patient with elevated factor VIII levels. Ann. Pharmacother. 47 (7\u20138), e29 (2013).","journal-title":"Ann. Pharmacother"},{"key":"81396_CR27","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/s13054-015-1109-0","volume":"19","author":"B Tardy-Poncet","year":"2015","unstructured":"Tardy-Poncet, B. et al. Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial. Crit. Care. 19, 396 (2015).","journal-title":"Crit. Care"},{"issue":"1","key":"81396_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/ajcp\/aqac131","volume":"159","author":"RA Hasan","year":"2023","unstructured":"Hasan, R. A., Pak, J., Kirk, C. J., Friedland-Little, J. M. & Chandler, W. L. Monitoring direct thrombin inhibitors with calibrated diluted Thrombin Time vs activated partial Thromboplastin Time in Pediatric patients. Am. J. Clin. Pathol. 159 (1), 60\u201368 (2023).","journal-title":"Am. J. Clin. Pathol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81396-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81396-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81396-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T11:19:36Z","timestamp":1732706376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81396-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["81396"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-81396-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"assertion":[{"value":"8 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JG received honoraria, research funding, and travel reimbursement from Alexion, Boehringer Ingelheim, CSL Behring, Instrumentation Laboratory, Johnson & Johnson, Mitsubishi Tanabe Pharma, Octapharma, Portola, and Takeda. SU received speaking fees from CSL Behring, Astra Zeneca, Arjo, Biomedica, Ekomed, NovoNordisk, and Roche. CD received speaking fees from CSL Behring, Astra Zeneca, Arjo, Biomedica, Ekomed, NovoNordisk, and Roche. ES received speaking fees from CSL Behring, Astra Zeneca, Arjo, Biomedica, Ekomed, NovoNordisk, Roche, B. Braun, and Bristol Myers Squibb. FS, SK, MW, and PQ declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of the Medical University of Vienna (EK 1937\/2022, 23\/02\/2023) and was performed in accordance with the principles of good clinical practice and the Declaration of Helsinki. Written informed consent was obtained from all the participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"29520"}}